Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ARCT
ARCTURUS THERAPEUTICS HOLDINGS INC.
NASDAQ
$15.19
▼ DOWN 6.06% (-0.98)

KEY STATISTICS

Market Cap$431.75 M
52w High$24.17
52w Low$5.50
Dividend Yield1.29%
FrequencySpecial
P/E-4.59
Volume1.62M
Shares Out.28.42M

COMPANY

LEADERSHIP

Joseph E. Payne
CHIEF EXECUTIVE
Joseph E. Payne

COMPENSATION 2026

Salary$750,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$1,691,000

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 22, 2013
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
109

PRICE TARGET

Target High$25.00
Target Low$25.00
Target Median$25.00
Target Consensus$25.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$8.00M
NOV
9
MON

SPLIT RECORD

DATETYPERATIO
2017-11-16Reverse1:7

PRICE

$15.19 ▼ DOWN 6.06% (−$0.98)
OVERLAYS
$14.80$15.20$15.609:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM15.19

About Arcturus Therapeutics Holdings Inc.

https://arcturusrx.com ↗

Arcturus Therapeutics is an RNA medicines company developing vaccines and therapies for infectious, liver, and respiratory rare diseases, with multiple programs and collaborations worldwide.

INDUSTRY

Biotechnology

A PRODUCT ARCTURUS THERAPEUTICS HOLDINGS INC. IS KNOWN FOR

KOSTAIVE®
KOSTAIVE®

KOSTAIVE® is the first approved self-amplifying mRNA COVID-19 vaccine, licensed in Japan and the EU, showcasing Arcturus's sa-mRNA platform with potential for broader, durable infectious disease protection.

COMPETITORS

COMPETITOR
BNTX COMPARE
MRNA COMPARE
PFE COMPARE
VRTX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Grant$3M $4.12M ▲$1.45M ▼$2.08M ▲
Collaboration Revenue$14.15M $3.08M ▼$610K ▼$880K ▲

Revenue by Geography

MapREGIONFY2022FY2024FY2025
Foreign countries$192.7M $138.4M ▼$67.1M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
78
LISTED HERE
19
RANKED BY POSITION SIZE
ARKG
2.21% · 2.9M
VTI
0.00% · 797.2K
XSU.TO
0.01% · 703.1K
SCHA
0.01% · 130.0K
PRFZ
0.05% · 92.0K
DFMC
0.01% · 69.5K
AVSC
0.03% · 56.1K
R2SC.L
0.01% · 44.7K
SBIO
0.22% · 35.2K
GSSC
0.05% · 33.8K
XRS2.DE
0.02% · 27.2K
WBIO.L
1.13% · 24.1K
NXTE
0.50% · 17.4K
RSSL
0.01% · 12.7K
MSGR
7.45% · 8.7K
SILX
1.46% · 8.5K
GERM
1.14% · 5.9K
JF
JFWD
2.21% · 3.0K
URTY
0.01% · 1.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
84.55%
HOLDERS
212
TOP 12 OF 212 · RANKED BY POSITION SIZE
Federated Hermes, Inc.
4.7M sh · $86.51M
Ark Investment Management LLC
2.9M sh · $19.5M
Blackrock Inc.
2.6M sh · $64.52M
Blackrock, Inc.
2.6M sh · $16.06M
Nikko Asset Management Americas, Inc.
2.3M sh · $17.65M
Sumitomo Mitsui Trust Holdings, Inc.
2.3M sh · $17.67M
Vanguard Group Inc
2.1M sh · $12.81M
Two Sigma Investments, LP
1.1M sh · $7.33M
State Street Corp
1.0M sh · $19.27M
Balyasny Asset Management L.P.
965.0K sh · $17.78M
Morgan Stanley
704.9K sh · $12.99M
Geode Capital Management, LLC
693.7K sh · $4.66M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR
Markels John
Purchase · 15.0K shares
2026-06-05
★
DIRECTOR
Slaoui Moncef
Purchase · 15.0K shares
2026-06-05
★
DIRECTOR
Marquet Magda
Purchase · 15.0K shares
2026-06-05
★
DIRECTOR
Marantz Jing L.
Purchase · 15.0K shares
2026-06-05

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OVERWEIGHT 2
NEUTRAL 2
7 GRADES IN THE LAST 12 MONTHS
B. Riley Securities BUY Citigroup BUY Piper Sandler OVERWEIGHT HC Wainwright & Co. NEUTRAL Wells Fargo OVERWEIGHT Guggenheim NEUTRAL BTIG BUY

SECTORS PEERS

PEERPRICE
ACHV$8.10COMPARE
ZURA$5.72COMPARE
AVIR$5.36COMPARE
FHTX$6.00COMPARE
SGMT$10.55COMPARE
VNDA$5.29COMPARE
TRDA$7.00COMPARE
VYGR$3.54COMPARE